Navigation Links
glargine in Medical News

AACE Response to Insulin Glargine Cancer Risk Articles in Diabetologia

JACKSONVILLE, Fla., June 29 /PRNewswire-USNewswire/ -- On June 26, 2009 several articles published online in Diabetologia by the European Association for the Study of Diabetes investigated the possible relationship between use of insulin glargine (Lantus, sanofi-aventis) and the developm...

Statement from IDF on studies suggesting possible link between insulin glargine and cancer

The International Diabetes Federation (IDF) today called for urgent assessment and responses from regulatory authorities into a possible link between the use of insulin glargine (an insulin analogue) and increased risk of cancer based on findings published on 26 June, 2009 in Diabetelogia , the j...

Expert Statement Issued about Lantus(R) Following Recent Publications in Diabetologia

...tions of registry analyses with Lantus(R) (insulin glargine [rDNA] injection) in Diabetologia . This board of...results regarding a potential link between insulin glargine use and an increased risk of cancer. "R...nce do not indicate an association between insulin glargine and cancer. About Diabetes Diabete...

FDA Tells Patients to Stick With Diabetes Drug Linked to Cancer

... whether an association between the use of insulin glargine and cancer truly exists." The agency also beli...ion echoed the FDA's position. "For patients using glargine and considering switching to another form of insul...nts to report side effects from the use of insulin glargine to the FDA's MedWatch Adverse Event Reporting Prog...

Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States

... The availability of Apidra(R) SoloSTAR(R), approved in the U.S. in February 2009, follows the approval and launch of Lantus(R) SoloSTAR(R) (insulin glargine [rDNA origin] injection) in 2007. People living with diabetes who use both Lantus(R) and Apidra(R) to help manage their blood sugar now have two pen d...

Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven

...AIAs for the treatment of type 2 diabetes (insulin glargine and insulin detemir) with human insulin, or compar...d various treatment schemes. This study on insulin glargine lasted 5 years; all the other studies lasted a max...table that in 7 of the 9 studies comparing insulin glargine and human insulin, the drugs were not used as norm...

Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R)

...ype 2 Diabetes BRIDGEWATER, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today its long-acting insulin Lantus(R) (insulin glargine [rDNA origin] injection) and rapid-acting insulin Apidra(R) (insulin glulisine [rDNA origin] injection) will be the primary 2009 sponsors of Team Type...

Amylin Pharmaceuticals Reports 2008 Financial Results

...ent of DURATION-3, the third in a planned program of superiority clinical studies of exenatide once weekly, comparing exenatide once weekly to insulin glargine in patients using oral diabetes medications. Results from this study are expected in the third quarter of 2009. Initiated DURATION-4 clinical...

Once-Daily Insulin Shot Proves Effective in Study

... insulin three times a day. The once-a-day formulation, known as insulin glargine (Lantus), is already on the market, as is insulin lispro (Humalog), which i...good and one is bad." The new study did show slight benefits for insulin glargine in terms of patient satisfaction and low blood sugar. But the study was fun...

Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend

...h type 2 diabetes found that the initiation of insulin therapy with insulin glargine (Lantus(R)) was associated with a lower incidence rate of subsequent myocar...ive analysis which found that initiation of insulin glargine in patients with type 2 diabetes was associated wit...
glargine in Medical Technology

New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes

SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- A head-to-head study announced today at the American Diabetes Association (ADA) meeting demonstrated that Levemir(R) (insulin detemir [rDNA origin] injection) can be used once-daily and had a comparable blood glucose response to insulin glargine ...

Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin

ORLANDO, Fla., Nov. 7 /PRNewswire-FirstCall/ -- A retrospective analysis of healthcare claims in more than 20,000 patients with type 2 diabetes from an integrated U.S. national managed care database found that the initiation of insulin therapy with insulin glargine was associated with a lower ...

Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study

COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinical results from the first of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The 26-week study is part of the LEAD(TM) (Liraglutide Effect and Action in Diabetes) programme and included 581 patients with type...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

...in combination with a sulfonylurea. Subjects were randomized to receive exenatide once weekly 2 milligrams by subcutaneous injection weekly or insulin glargine injections administered daily in a variable dose determined by patient blood sugar levels. There was no lead-in or wash-out period. The primary endpoi...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

... the long-term, 5-year study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progressio...ngest randomized controlled study with insulin glargine versus NPH human insulin ," said lead investig... to 7.8% and 7.6% for all patients in the insuline glargine and NPH insulin groups respectively). NPH insulin ...

Sanofi-aventis Stands Behind the Safety of Lantus(R)

...e drawn regarding a possible causal relationship between Lantus(R) (insulin glargine [rDNA] injection) use and the occurrence of malignancies, as the authors of...e gold standard of evidence, do not indicate an association between insulin glargine and cancer. "Given the extensive clinical evidence covering over 70,0...

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients

...% and </=11.0%) despite insulin with/ without oral anti-hyperglycemic therapy were randomized to a 52-week course of either AFRESA (TI) and bedtime glargine insulin (G) (n=334) or premixed biaspart 70/30 insulin BID (BPA 70/30) twice-a-day (n=343). The primary endpoint was mean change from baseline to week...

New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar

...nsulin Glulisine on Glycemic Control in Type 2 Diabetes Patients on Insulin glargine and Oral Drugs," evaluating patients adding prandial insulin Apidra(R) (ins... 2 meals or 3 meals daily, already taking basal insulin, Lantus(R) (insulin glargine [rDNA origin] injection), with or without oral antidiabetic drugs (OADs).Th...

Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback

...completed enrollment in the fourth quarter. This approximately 450 patient, open-label, superiority study compares exenatide once weekly with insulin glargine on a background of oral agent therapy. Results are expected in the third quarter of 2009. DURATION-2 completed enrollment in the third quarter...

FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes

...twice daily as basal insulin. The majority of the patients received insulin glargine as part of their basal-prandial regimen (69.7% and 72% in the Apidra(R) and...s with type 2 diabetes. Apidra(R) is from the maker of Lantus(R) (insulin glargine [rDNA origin] injection), the number one prescribed insulin.* About Lantu...
glargine in Biological Technology

Sanofi-aventis Announces Second Quarter 2009 Results

...as the authors of the study point out. Clinical studies, which represent the gold standard of evidence, do not indicate an association between insulin glargine and cancer. Patient safety being the primary concern of sanofi-aventis, the company commissioned a board of international specialists in endoc...

FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen

... diabetes or adults with type 2 diabetes. The approval of Apidra(R) SoloSTAR(R) follows the approval and launch of Lantus(R) SoloSTAR(R) (insulin glargine [rDNA origin] injection) in 2007. People living with diabetes who use both Lantus(R) and Apidra(R) to help manage their blood sugar will now have two ...

Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes

...European Association for the Study of Diabetes (EASD) 44th Annual Meeting demonstrating that the "basal plus" insulin strategy with LANTUS(R) (insulin glargine (rDNA origin) injection) once daily (basal insulin) and APIDRA(R) once daily (prandial insulin) (insulin glulisine (rDNA origin) injection) administer...

Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award

...s the OptiSet(R) disposable pen, the OptiClik(R) and OptiPen(R) Pro reusable pens, and the Autopen(R) 24 from Owen Mumford. About LANTUS(R) (insulin glargine [rDNA origin]) LANTUS(R) is indicated for once-daily subcutaneous administration in the treatment of adult patients with type 2 diabetes mellitus wh...

Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes

... in combination with oral medications, but I still wasn't getting my blood sugar under control. Then about five years ago, we added Lantus(R) (insulin glargine [rDNA origin] injection), a once-daily, long-acting insulin to my overall treatment plan." The former Sopranos actress recently began using Lantus(R)...
Other Tags
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... East Liverpool, OH (PRWEB) May 22, 2015 ... today announced that Kyle Johnson, the health system’s Chief ... pursue other interests. Johnson has served as the company ... announced Wesley West will be joining the health system ... operations on an interim basis, while the Board of ...
(Date:5/22/2015)... Halifax, NS (PRWEB) May 22, 2015 ... into a sale agreement with US-based health brand Nature’s ... Ascenta Skin brand. Retention of Ascenta Skin is an ... St-Onge is excited about this opportunity to further develop ... industry. , Ascenta Skin is a breakthrough, anti-aging ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Combination ... treatment option for chronic obstructive pulmonary disorder (COPD) ... plc and AstraZeneca plc as well as Germany’s ... share and position. But will market payers, clinicians ... already well-entrenched products to completely new ones? , ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/10/2015)... Sweden , May 11, 2015 ... fingerprint sensors FPC1025 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of + 1 000 MSEK ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
Other Contents